10-hydroxycamptothecin has been researched along with Breast Cancer in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Deng, H; Huang, P; Jin, X; Sun, P; Wang, N; Zhu, X | 1 |
| Bo, M; Chen, B; Chen, M; Gao, S; Li, L; Ma, Q; Yuan, K; Zhang, W; Zhu, L | 1 |
| Li, P; Ran, H; Ren, J; Wang, Z; Xia, Y; Zhao, H; Zhou, Z; Zhu, L | 1 |
| Chen, Y; Fan, Z; Hou, Z; Li, Y; Lin, J; Ma, J; Su, G; Xie, L; Zhang, H; Zhang, Y; Zhu, X | 1 |
| Jiang, Q; Liu, J; Luo, X; Yang, Z; Zhang, X | 1 |
| Chen, Z; Feng, Y; Guo, R; He, M; Hong, Z; Kong, X; Li, M; Li, Y; Tian, R; Wang, J; Wu, W; Yu, K; Yu, M | 1 |
| Liu, W; Zhang, R | 1 |
| Agrawal, S; Nan, L; Wang, H; Yu, D; Zhang, R | 1 |
8 other study(ies) available for 10-hydroxycamptothecin and Breast Cancer
| Article | Year |
|---|---|
"Bottom-up" Construction of Multi-Polyprodrug-Arm Hyperbranched Amphiphiles for Cancer Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Female; Humans; Mice; Micelles; Polymers; Prodrugs; Rats; Rats, Sprague-Dawley; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Preclinical Evaluation and Monitoring of the Therapeutic Response of a Dual Targeted Hyaluronic Acid Nanodrug.
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Drug Carriers; Heterografts; Humans; Hyaluronic Acid; Mice; Nanoparticles | 2017 |
Peptide-Functionalized Phase-Transformation Nanoparticles for Low Intensity Focused Ultrasound-Assisted Tumor Imaging and Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Mice, Nude; Molecular Imaging; Nanoparticles; Optical Imaging; Peptides; Phase Transition; Ultrasonography | 2018 |
Integration of phospholipid-hyaluronic acid-methotrexate nanocarrier assembly and amphiphilic drug-drug conjugate for synergistic targeted delivery and combinational tumor therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Carriers; Drug Compounding; Drug Synergism; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Hyaluronic Acid; MCF-7 Cells; Methotrexate; Mice; Mice, Nude; Nanoparticles; Phosphatidylethanolamines; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Targeted delivery of 10-hydroxycamptothecin to human breast cancers by cyclic RGD-modified lipid-polymer hybrid nanoparticles.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Humans; Lipids; Materials Testing; MCF-7 Cells; Molecular Targeted Therapy; Nanocapsules; Oligopeptides; Polymers | 2013 |
A novel multifunctional poly(amidoamine) dendrimeric delivery system with superior encapsulation capacity for targeted delivery of the chemotherapy drug 10-hydroxycamptothecin.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chemistry, Pharmaceutical; Dendrimers; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Endocytosis; Female; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Integrin alphaVbeta3; Kinetics; Male; MCF-7 Cells; Peptides, Cyclic; Polyamines; Prostatic Neoplasms; Solubility; Surface Properties; Technology, Pharmaceutical | 2014 |
Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Female; Humans; Proto-Oncogene Proteins c-bcl-2; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Camptothecin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA, Antisense; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Nuclear Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2001 |